Possible involvement of protein kinase C in the attenuation of [D- Ala2, NMePhe4, Gly-ol5]enkephalin-induced antinociception in diabetic mice

European Journal of Pharmacology

Volumn 339, Issue 1, 1997, Pages 27-31

  Ohsawa, Masahiro ^a   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

(Mouse); Antinociception; Calphostin C; DAMGO ( D Ala2,NMePhe4,Gly ol5)enkephalin); Diabetes; Protein kinase C

Indexed keywords

CALPHOSTIN C; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GLUCOSE; PHORBOL DIBUTYRATE; PROTEIN KINASE C;

ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; MALE; MOUSE; NOCICEPTIVE RECEPTOR; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; ENZYME INHIBITORS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED ICR; NAPHTHALENES; NOCICEPTORS; PHORBOL 12,13-DIBUTYRATE; PROTEIN KINASE C; REFERENCE VALUES;

EID: 0031578552     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01365-4     Document Type: Article

References (24)

1. Ahlgren S.C., Levine J.D. Protein kinase C inhibitors decrease hyperalgesia and C-fiber hyperexcitability in the streptozotocin-diabetic rat. J. Neurophysiol. 72:1994;684-692.
2. Chen Y., Mestek A., Liu J., Hurley J., Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44:1993;8-12.
3. Craven P.A., DeRubertis F.R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. J. Clin. Invest. 83:1989;1667-1675.
4. Evans C., Keith D., Morrison H., Magendzo K., Edwards R. Cloning of a delta receptor by functional expression. Science. 258:1992;1952-1955.
5. Haley M.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
6. Inoguchi T., Battan R., Handler E., Sportsman J.R., Health W., King G.L. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA. 89:1992;11059-11063.
7. Kamei J., Kawashima N., Kasuya Y. Role of spleen or spleen produces in the deficiency in morphine-induced analgesia in diabetic mice. Brain Res. 576:1992;139-142.
8. Kamei J., Ohhashi Y., Aoki T., Kawashima N., Kasuya Y. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists. Brain Res. 571:1992;199-203.
9. 2-opioid receptors. Neurosci. Lett. 165:1994;141-143.
10. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The delta-opioid receptor: Isolation of cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. USA. 89:1992;12048-12052.
11. King, G.L., Johnson, S., Wu, G., 1990. Possible growth modulators involved in the pathogenesis of diabetic proliferative retinopathy. In: Westermark, B., Betscholtz, C., Hokfelt, B. (Eds.), Growth Factors in Health and Diseases. Elsevier, Amsterdam, pp. 303-317.
12. Kobayashi E., Nakano N., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;548-553.
13. Liang Y., Mestek A., Yu L., Carr L.G. Cloning and characterization of the promoter region of the mouse μ-opioid receptor gene. Brain Res. 679:1995;82-88.
14. Miotto, K., Magendzo, K., Evans, C.J., 1995. Molecular characterization of opioid receptors. In: Tseng, L.F. (Ed.), The Pharmacology of Opioid Peptides. Harwood Academic Publishers, Switzerland, pp. 57-71.
15. Narita M., Narita M., Mizoguchi H., Tseng L.F. Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered μ-opioid receptor agonist in the mouse. Eur. J. Pharmacol. 280:1995;R1-R3.
16. Narita M., Ohsawa M., Mizoguchi H., Kamei J., Tseng L.F. Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by μ-but not ε-opioid receptor agonist in the mouse. Neuroscience. 76:1996;291-298.
17. Nishizuka Y. The molecular heterogeneity to protein kinase C and its implication for cellular regulation. Nature. 334:1988;661-665.
18. Shearman M.S., Sekiguchi K., Nishizuka Y. Modulation of ion channel activity: A key function of the protein kinase C enzyme family. Pharmacol. Rev. 41:1989;211-237.
19. Shiba T., Inoguchi T., Sportsman R., Health W., Bursell S.E., King G.L. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol. 265:1993;E783-E793.
20. Simon G.S., Dewey W.L. Narcotics and diabetes I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J. Pharmacol. Exp. Ther. 218:1981;318-323.
21. Tallarida, R.J., Murray, R.B., 1987. Manual of Pharmacological Calculation with Computer Programs. Springer-Verlag, New York, NY.
22. Tanaka Y., Kashiwagi A., Ogawa T., Abe N., Asahina T., Ikebuchi M., Takagi Y., Shigeta Y. Effect of verapamil on cardiac protein kinase C activity in diabetic rats. Eur. J. Pharmacol. 200:1991;353-356.
23. Wolf B.A., Williamson J.R., Easom R.A., Chang K., Sherman W.R., Turk J. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J. Clin. Invest. 87:1990;31-38.
24. Yasuda K., Raynor K., Kong H., Breder C., Takeda J., Reisine T., Bell G.I. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Natl. Acad. Sci. USA. 90:1993;6736-6740.